# A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

> **NCT04434469** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** RO7297089

## Key facts

- **NCT ID:** NCT04434469
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-08
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04434469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04434469, "A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04434469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*